Clinical trial
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or…
NCT00070551 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00070551 |
|---|---|
| Title | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia |
| Official title | A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22 and 1 more |
| Intervention type | Biological, Drug, Other |
| Interventions | GTI-2040, cytarabine, pharmacological study, laboratory biomarker analysis |
| Enrollment | 51 |
| Start date | Sep 1, 2003 |
| Primary completion | Feb 1, 2009 |
| First posted | Oct 7, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: